| scholarly article | Q13442814 |
| P50 | author | Brian Druker | Q373427 |
| Jeffrey W. Tyner | Q42182973 | ||
| Christopher J. Burns | Q42981129 | ||
| Emmanuelle Fantino | Q47502150 | ||
| Lisa J. Wood | Q55207369 | ||
| Marc M Loriaux | Q114442747 | ||
| P2093 | author name string | Michael W Deininger | |
| Karl J Aichberger | |||
| Jutta Deininger | |||
| Thomas G Bumm | |||
| P2860 | cites work | JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis | Q24609999 |
| The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia | Q27266125 | ||
| EGFR mutation and resistance of non-small-cell lung cancer to gefitinib | Q27824829 | ||
| Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. | Q27851427 | ||
| A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera | Q28241887 | ||
| Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis | Q29614337 | ||
| Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification | Q29618788 | ||
| A gain-of-function mutation of JAK2 in myeloproliferative disorders | Q29618851 | ||
| Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders | Q29618853 | ||
| European consensus on grading bone marrow fibrosis and assessment of cellularity | Q33221061 | ||
| RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia | Q33306326 | ||
| Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. | Q33369428 | ||
| JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. | Q33371084 | ||
| Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors | Q34768390 | ||
| MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia | Q34770384 | ||
| Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model | Q35849674 | ||
| The development of imatinib as a therapeutic agent for chronic myeloid leukemia | Q35993288 | ||
| Activation mechanisms of STAT5 by oncogenic Flt3-ITD. | Q40159800 | ||
| Characterization of murine JAK2V617F-positive myeloproliferative disease | Q40200859 | ||
| Janus kinase 2: a critical target in chronic myelogenous leukemia | Q40259925 | ||
| Tumor necrosis factor-alpha expressed constitutively in erythroid cells or induced by erythropoietin has negative and stimulatory roles in normal erythropoiesis and erythroleukemia | Q40695064 | ||
| Characterization of an interleukin-6-mediated autocrine growth loop in the human multiple myeloma cell line, U266. | Q41696897 | ||
| Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations | Q42742043 | ||
| Improved co-expression of multiple genes in vectors containing internal ribosome entry sites (IRESes) from human genes. | Q45884844 | ||
| Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice | Q46832173 | ||
| Cachectin/tumor necrosis factor-alpha alters red blood cell kinetics and induces anemia in vivo | Q50195798 | ||
| Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases | Q81097264 | ||
| P433 | issue | 25 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 5232-5240 | |
| P577 | publication date | 2010-04-12 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms | |
| P478 | volume | 115 |
| Q41883646 | A Drosophila model of myeloproliferative neoplasm reveals a feed-forward loop in the JAK pathway mediated by p38 MAPK signalling |
| Q33623277 | AKT is a therapeutic target in myeloproliferative neoplasms |
| Q56978683 | Activated kinase screening identifies the IKBKE oncogene as a positive regulator of autophagy |
| Q38018908 | Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors |
| Q54979332 | Autocrine Tnf signaling favors malignant cells in myelofibrosis in a Tnfr2-dependent fashion. |
| Q52584568 | Autocrine activation of JAK2 by IL-11 promotes platinum drug resistance. |
| Q33402522 | Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib |
| Q34485103 | CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms. |
| Q42725814 | Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2. |
| Q36797253 | Characterization of the TGF-β1 signaling abnormalities in the Gata1low mouse model of myelofibrosis |
| Q26777398 | Circulating Cytokine Levels as Markers of Inflammation in Philadelphia Negative Myeloproliferative Neoplasms: Diagnostic and Prognostic Interest |
| Q45916590 | Circulating levels of MCP-1, sIL-2R, IL-15, and IL-8 predict anemia response to pomalidomide therapy in myelofibrosis. |
| Q38994716 | Combination of PIM and JAK2 inhibitors synergistically suppresses MPN cell proliferation and overcomes drug resistance |
| Q36318162 | Combination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-α 2a specifically targets JAK2V617F-positive polycythemia vera cells |
| Q36776428 | Comprehensive review of JAK inhibitors in myeloproliferative neoplasms. |
| Q37293986 | Cooperative effects of Janus and Aurora kinase inhibition by CEP701 in cells expressing Jak2V617F. |
| Q34302770 | Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms |
| Q60907870 | Defective negative regulation of Toll-like receptor signaling leads to excessive TNF-α in myeloproliferative neoplasm |
| Q45966435 | Determining the role of inflammation in the selection of JAK2 mutant cells in myeloproliferative neoplasms. |
| Q30846580 | Drug screening on Hutchinson Gilford progeria pluripotent stem cells reveals aminopyrimidines as new modulators of farnesylation. |
| Q38164139 | Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application |
| Q37555309 | Effect of NS-018, a selective JAK2V617F inhibitor, in a murine model of myelofibrosis |
| Q33404574 | Emerging drugs for myelofibrosis |
| Q38025160 | Emerging targeted therapies in myelofibrosis |
| Q38143243 | Emerging therapies for the treatment of chronic Philadelphia chromosome-negative myeloproliferative neoplasm-associated myelofibrosis |
| Q35005652 | Enu mutagenesis identifies a novel platelet phenotype in a loss-of-function Jak2 allele |
| Q35079398 | Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia |
| Q49758040 | Expansion of EPOR-negative macrophages besides erythroblasts by elevated EPOR signaling in erythrocytosis mouse models |
| Q36462938 | Expression of Tumor-Related Macrophages and Cytokines After Surgery of Triple-Negative Breast Cancer Patients and its Implications. |
| Q94445996 | Fedratinib in myelofibrosis |
| Q57219306 | Heterogeneous expression of cytokines accounts for clinical diversity and refines prognostication in CMML |
| Q30251920 | Histone deacetylase inhibitor pracinostat in doublet therapy: a unique strategy to improve therapeutic efficacy and to tackle herculean cancer chemoresistance |
| Q38254425 | How we manage JAK inhibition in allogeneic transplantation for myelofibrosis. |
| Q36395621 | IFNγR signaling mediates alloreactive T-cell trafficking and GVHD |
| Q38665092 | Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit. |
| Q33628532 | Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden |
| Q38077992 | Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012. |
| Q36745581 | Intrinsic resistance to JAK2 inhibition in myelofibrosis |
| Q38691019 | Investigational Janus kinase inhibitors in development for myelofibrosis |
| Q34648724 | Investigational Janus kinase inhibitors. |
| Q43246867 | JAK Inhibitors and other Novel Agents in Myeloproliferative Neoplasms: Are We Hitting the Target? |
| Q47099145 | JAK1/2 Inhibitors AZD1480 and CYT387 Inhibit Canine B-Cell Lymphoma Growth by Increasing Apoptosis and Disrupting Cell Proliferation. |
| Q21285040 | JAK2 Inhibition: Reviewing a New Therapeutical Option in Myeloproliferative Neoplasms |
| Q47095048 | JAK2 aberrations in childhood B-cell precursor acute lymphoblastic leukemia |
| Q38001733 | JAK2 inhibition for the treatment of hematologic and solid malignancies |
| Q36232824 | JAK2 inhibition has different therapeutic effects according to myeloproliferative neoplasm development in mice |
| Q37123250 | JAK2 inhibitor combined with DC-activated AFP-specific T-cells enhances antitumor function in a Fas/FasL signal-independent pathway |
| Q38044736 | JAK2 inhibitors in the treatment of myeloproliferative neoplasms. |
| Q37950581 | JAK2 inhibitors: are they the solution? |
| Q37168138 | JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms |
| Q38756741 | Jak1-STAT3 Signals Are Essential Effectors of the USP6/TRE17 Oncogene in Tumorigenesis |
| Q55506567 | Jak2 Tyrosine Kinase: A Potential Therapeutic Target for AT1 Receptor Mediated Cardiovascular Disease. |
| Q37815509 | Janus kinase 2 inhibitors in myeloproliferative disorders |
| Q37998574 | Janus kinase inhibition and its effect upon the therapeutic landscape for myelofibrosis: from palliation to cure? |
| Q37833893 | Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond |
| Q34021753 | Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms |
| Q35814037 | Kinase inhibitors in the treatment of immune-mediated disease |
| Q34307423 | Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening |
| Q35805105 | Limited efficacy of BMS-911543 in a murine model of Janus kinase 2 V617F myeloproliferative neoplasm |
| Q62818096 | Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis |
| Q33432406 | Managing patients with myelofibrosis and low platelet counts |
| Q38081267 | Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance |
| Q30244032 | Momelotinib in myelofibrosis: JAK1/2 inhibitor with a role in treating and understanding the anemia |
| Q54998956 | Momelotinib therapy for myelofibrosis: a 7-year follow-up. |
| Q47671095 | Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial |
| Q89525831 | Morpholine As a Scaffold in Medicinal Chemistry: An Update on Synthetic Strategies |
| Q38046320 | Myeloproliferative neoplasm animal models |
| Q37877727 | Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy? |
| Q37869152 | New JAK2 inhibitors for myeloproliferative neoplasms |
| Q37069633 | Novel and emerging therapies for the treatment of polycythemia vera |
| Q90622530 | Nuclear-Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis |
| Q38699339 | Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs). |
| Q36529881 | Patterns of hydroxyurea use and clinical outcomes among patients with polycythemia vera in real-world clinical practice: a chart review |
| Q50128724 | Pharmacokinetics and Safety of Momelotinib in Subjects With Hepatic or Renal Impairment |
| Q34301568 | Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect |
| Q64934456 | Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma. |
| Q38027835 | Potential use of STAT3 inhibitors in targeted prostate cancer therapy: future prospects |
| Q38154517 | Preclinical models for drug selection in myeloproliferative neoplasms. |
| Q42090824 | Ruxolitinib for the treatment of myelofibrosis: its clinical potential |
| Q33397219 | Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis |
| Q38100790 | Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians |
| Q34194226 | SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies. |
| Q49993088 | SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis |
| Q33406238 | Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis |
| Q38261371 | Selective JAK inhibitors |
| Q33419762 | Selective Janus associated kinase 1 inhibition as a therapeutic target in myelofibrosis |
| Q27026031 | Signal transduction in the chronic leukemias: implications for targeted therapies |
| Q38815335 | Src and STAT3 inhibitors synergize to promote tumor inhibition in renal cell carcinoma |
| Q38570615 | TBK1 inhibitors: a review of patent literature (2011 - 2014). |
| Q39486061 | TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties |
| Q35608167 | TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms |
| Q37705457 | Targeted Disruption of the JAK2/STAT3 Pathway in Combination with Systemic Administration of Paclitaxel Inhibits the Priming of Ovarian Cancer Stem Cells Leading to a Reduced Tumor Burden. |
| Q26860796 | Targeting JAK2 in the therapy of myeloproliferative neoplasms |
| Q35145319 | Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth |
| Q30666276 | Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance |
| Q89469502 | Targeting the IκB Kinase Enhancer and Its Feedback Circuit in Pancreatic Cancer |
| Q35571892 | The Jak2 inhibitor, G6, alleviates Jak2-V617F-mediated myeloproliferative neoplasia by providing significant therapeutic efficacy to the bone marrow |
| Q50099353 | The Relative Bioavailability, Food Effect, and Drug Interaction With Omeprazole of Momelotinib Tablet Formulation in Healthy Subjects |
| Q27021968 | The evolving treatment paradigm in myelofibrosis |
| Q54571865 | The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells. |
| Q34640790 | The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML. |
| Q34337681 | The small molecule inhibitor G6 significantly reduces bone marrow fibrosis and the mutant burden in a mouse model of Jak2-mediated myelofibrosis. |
| Q34575802 | The stilbenoid tyrosine kinase inhibitor, G6, suppresses Jak2-V617F-mediated human pathological cell growth in vitro and in vivo |
| Q26752940 | Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromes |
| Q37860336 | Therapeutic approaches in myelofibrosis. |
| Q38046321 | Therapy with JAK2 inhibitors for myeloproliferative neoplasms |
Search more.